IQVIA Holdings Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ari Bousbib
- Full Time Employees
- 94,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2400 Ellis Road Durham NC United States of America 27703
- IPO Date
- May 9, 2013
- CIK
- 0001478242
- Website
- iqvia.com
- Similar Companies
- Business
- IQVIA Holdings Inc operates as a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries. The company offers a comprehensive portfolio including clinical trial services; commercial insights; healthcare intelligence; real-world evidence generation; and advanced data analytics powered by IQVIA Connected Intelligence™, Healthcare-grade AI™, and big data resources. Its technology solutions encompass software platforms for orchestrated customer engagement, data management, and commercial orchestration, supported by partnerships with leading technology providers such as NVIDIA and Veeva Systems. IQVIA's service offerings span drug development, regulatory consulting, market access, and patient centricity solutions, targeting pharmaceutical, biotechnology, and medical device companies worldwide. Headquartered in Durham, North Carolina, and founded through the 2016 merger of Quintiles and IMS Health, IQVIA operates in more than 100 countries with approximately 88,000 employees. Recent company developments include a strategic partnership with NVIDIA to integrate generative and agentic AI within clinical research workflows, accelerating innovation and efficiency in drug development. IQVIA also expanded a clinical and commercial collaboration with Veeva Technologies to enhance interoperability and deliver streamlined solutions for customers in clinical development and commercialization. In 2024 and 2025, IQVIA advanced its healthcare data analytics capabilities through acquisitions of healthcare technology firms, reinforcing its technology portfolio and enabling broader service offerings. Additionally, the company continues to support pharmaceutical product launches globally, tracking and analyzing launch excellence to optimize commercial success across multiple therapeutic areas. IQVIA's ongoing investments in AI and integrated technology ecosystems position it at the forefront of healthcare intelligence and life sciences services innovation.
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy?
First Trust Advisors LP Has $4.78 Million Stock Position in IQVIA Holdings Inc. $IQV
Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
Empowered Funds LLC Raises Holdings in IQVIA Holdings Inc. $IQV
Insider Selling: IQVIA (NYSE:IQV) Insider Sells $1,245,800.00 in Stock
An IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should Know
An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Know
An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion
Amundi Has $148.20 Million Holdings in IQVIA Holdings Inc. $IQV
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?
IQVIA: A Great Business At The Wrong Price (Rating Downgrade)
IQVIA (IQV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
IQVIA Holdings Inc. (IQV) Q2 2026 Earnings Call Transcript
IQVIA Q2 Earnings Call Highlights
This Healthcare Stock Is Today's Best in the S&P 500
IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised
IQVIA Holdings (IQV) Q2 Earnings and Revenues Beat Estimates